STIT employs drugs such as BRAF inhibitors (dabrafenib, vemurafenib, encorafenib) that block the activity of proteins made by mutant BRAF genes; and MEK inhibitors (trametinib, cobimetinib, binimetinib) that block proteins (MEK1 and MEK2) which affect the growth and survival of cancer cells [10]. The gene discussed is BRAF; the disease is cancer.